| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Sofosbuvir/Velpatasvir/Voxilaprevir |
| Brand | Vosevi® |
| Indication | For the treatment of chronic hepatitis C virus (HCV) infection in adults – pangenotypic i.e. all genotypes (GT1, 2, 3, 4, 5 and 6). |
| Assessment Process | |
| Rapid review commissioned | 19/09/2017 |
| Rapid review completed | 15/11/2017 |
| Rapid review outcome | Full pharmacoeconomic assessment not recommended |